XML 57 R36.htm IDEA: XBRL DOCUMENT v3.23.3
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2023202220232022
Segment Net Sales    
United States$869.9 $786.8 $2,614.3 $2,337.1 
Europe317.8 291.9 989.2 901.8 
Japan107.2 130.9 321.2 416.9 
Rest of World181.2 160.9 529.0 449.1 
Total segment net sales$1,476.1 $1,370.5 $4,453.7 $4,104.9 
Segment Operating Income    
United States$571.7 $535.0 $1,727.5 $1,596.0 
Europe168.5 156.0 527.9 487.1 
Japan63.9 87.3 190.7 282.7 
Rest of World80.3 63.7 230.9 178.0 
Total segment operating income$884.4 $842.0 $2,677.0 $2,543.8 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2023202220232022
Net Sales Reconciliation    
Segment net sales$1,476.1 $1,370.5 $4,453.7 $4,104.9 
Foreign currency4.8 (51.5)17.0 (70.8)
Consolidated net sales$1,480.9 $1,319.0 $4,470.7 $4,034.1 
Pre-tax Income Reconciliation    
Segment operating income$884.4 $842.0 $2,677.0 $2,543.8 
Unallocated amounts:    
Corporate items(473.9)(415.6)(1,435.2)(1,285.4)
Special charge (Note 4)— (66.8)— (66.8)
Intellectual property agreement and litigation (expense) income, net(2.2)2.4 (193.6)(10.8)
Change in fair value of contingent consideration liabilities— 12.5 26.2 36.3 
Foreign currency10.1 27.9 59.6 83.6 
Consolidated operating income418.4 402.4 1,134.0 1,300.7 
Non-operating income20.9 4.9 42.4 7.4 
Consolidated pre-tax income$439.3 $407.3 $1,176.4 $1,308.1 
Schedule of Enterprise-Wide Information
The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2023202220232022
Net Sales by Geographic Region    
United States$869.9 $786.8 $2,614.3 $2,337.1 
Europe322.3 270.1 989.6 884.0 
Japan108.4 104.1 340.4 362.5 
Rest of World180.3 158.0 526.4 450.5 
$1,480.9 $1,319.0 $4,470.7 $4,034.1 
Net Sales by Major Product Group    
Transcatheter Aortic Valve Replacement$960.9 $862.3 $2,900.4 $2,650.5 
Transcatheter Mitral and Tricuspid Therapies52.4 29.7 141.6 84.6 
Surgical Structural Heart246.6 219.7 751.1 669.0 
Critical Care221.0 207.3 677.6 630.0 
$1,480.9 $1,319.0 $4,470.7 $4,034.1